Anebulo Pharmaceuticals Q2 net loss narrows

Reuters

1 hour ago

Anebulo Pharmaceuticals <a href="https://laohu8.com/S/QTWO">Q2</a> net loss narrows

Overview

Clinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mln
Company to voluntarily delist from Nasdaq, citing cost concerns
Operating expenses for fiscal Q2 remain flat at $2.6 mln

Outlook

Company plans to delist from Nasdaq by February 27, 2026

Result Drivers

OPERATING EXPENSES - Total operating expenses remained flat at $2.6 mln compared to the same period last year

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 EPS		-$0.05
Q2 Net Income		-$2 mln
Q2 Basic EPS		-$0.05
Q2 Operating Expenses		$2.60 mln

Press Release: ID:nBw7zX9TDa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611085589"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611085589\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611085589?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611085589","market":"fut","top_or_hot":-1,"title":"Anebulo Pharmaceuticals Q2 net loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anebulo Pharmaceuticals <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss narrows</title></head><body>Overview<ul><li>Clinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mln</li><li>Company to voluntarily delist from Nasdaq, citing cost concerns</li><li>Operating expenses for fiscal Q2 remain flat at $2.6 mln</li></ul>Outlook<ul><li>Company plans to delist from Nasdaq by February 27, 2026</li></ul>Result Drivers<ul><li>OPERATING EXPENSES - Total operating expenses remained flat at $2.6 mln compared to the same period last year</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q2 EPS</td><td></td><td>-$0.05</td><td></td></tr><tr><td>Q2 Net Income</td><td></td><td>-$2 mln</td><td></td></tr><tr><td>Q2 Basic EPS</td><td></td><td>-$0.05</td><td></td></tr><tr><td>Q2 Operating Expenses</td><td></td><td>$2.60 mln</td><td></td></tr></tbody></table>Press Release: ID:nBw7zX9TDaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anebulo Pharmaceuticals Q2 net loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnebulo Pharmaceuticals Q2 net loss narrows\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nReuters \n2026-02-13 05:27\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Anebulo Pharmaceuticals <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss narrows</title></head><body>Overview<ul><li>Clinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mln</li><li>Company to voluntarily delist from Nasdaq, citing cost concerns</li><li>Operating expenses for fiscal Q2 remain flat at $2.6 mln</li></ul>Outlook<ul><li>Company plans to delist from Nasdaq by February 27, 2026</li></ul>Result Drivers<ul><li>OPERATING EXPENSES - Total operating expenses remained flat at $2.6 mln compared to the same period last year</li></ul>Key Details<table><tbody><tr><td>Metric</td><td>Beat/Miss</td><td>Actual</td><td>Consensus Estimate</td></tr><tr><td>Q2 EPS</td><td></td><td>-$0.05</td><td></td></tr><tr><td>Q2 Net Income</td><td></td><td>-$2 mln</td><td></td></tr><tr><td>Q2 Basic EPS</td><td></td><td>-$0.05</td><td></td></tr><tr><td>Q2 Operating Expenses</td><td></td><td>$2.60 mln</td><td></td></tr></tbody></table>Press Release: ID:nBw7zX9TDaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81I2:1","article_id":"2611085589","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611085589","pubTimestamp":1770931678,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Anebulo Pharmaceuticals Q2 net loss narrowsOverviewClinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mlnCompany to voluntarily delist from Nasdaq, citing cost concernsOperating ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ANEB":"Anebulo Pharmaceuticals, Inc.","BK4539":"次新股"},"translate_title":"Anebulo制药第二季度净亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANEB":0.9},"content_text":"Anebulo Pharmaceuticals Q2 net loss narrowsOverviewClinical-stage pharma's fiscal Q2 net loss narrows to $2.0 mln from $2.5 mlnCompany to voluntarily delist from Nasdaq, citing cost concernsOperating expenses for fiscal Q2 remain flat at $2.6 mlnOutlookCompany plans to delist from Nasdaq by February 27, 2026Result DriversOPERATING EXPENSES - Total operating expenses remained flat at $2.6 mln compared to the same period last yearKey DetailsMetricBeat/MissActualConsensus EstimateQ2 EPS-$0.05Q2 Net Income-$2 mlnQ2 Basic EPS-$0.05Q2 Operating Expenses$2.60 mlnPress Release: ID:nBw7zX9TDaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}